Drugs / Allogenic Islet Cell Transplantation
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03698396 | Aug 2019 → Nov 2021 | type 1 diabetes mellitus | Kenneth Brayman, MD | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogenic Islet Cell Transplantation | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03698396 ↗ |
| Action | Restore | “therefore restore insulin production and ameliorate glycemic instability in patients with T1D” NCT03698396 ↗ |
| Modality | Cell therapy | “Biological: Allogenic Islet Cell Transplantation” NCT03698396 ↗ |